An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Summary

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hypertension (HTN)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Novartis Pharmaceuticals

Last updated on ClinicalTrials.gov

July 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites